These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25845709)

  • 21. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System.
    Cox L; Larenas-Linnemann D; Lockey RF; Passalacqua G
    J Allergy Clin Immunol; 2010 Mar; 125(3):569-74, 574.e1-574.e7. PubMed ID: 20144472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaphylactic reactions during immunotherapy.
    Rezvani M; Bernstein DI
    Immunol Allergy Clin North Am; 2007 May; 27(2):295-307, viii. PubMed ID: 17493504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study.
    Confino-Cohen R; Goldberg A
    Ann Allergy Asthma Immunol; 2010 Jan; 104(1):73-8. PubMed ID: 20143649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of respiratory allergy with allergy immunotherapy tablets.
    Bachert C
    Allergy; 2011 Jul; 66 Suppl 95():57-9. PubMed ID: 21668858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safety of allergen immunotherapy: a literature review.
    Cook PR; Farias C
    Ear Nose Throat J; 1998 May; 77(5):378-9, 383-8. PubMed ID: 9615518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical considerations in the use of sublingual immunotherapy for allergic rhinitis.
    Lee S; Nolte H; Benninger MS
    Am J Rhinol Allergy; 2015; 29(2):106-14. PubMed ID: 25785750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy.
    Hsu NM; Reisacher WR
    Int Forum Allergy Rhinol; 2012; 2(4):280-4. PubMed ID: 22434716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations.
    Cox L; Calderón M; Pfaar O
    Immunotherapy; 2012 Jun; 4(6):601-16. PubMed ID: 22788128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality assurance ofallergen-specific immunotherapy during a national outbreak of anaphylaxis: results of a continuous sentinel event surveillance system.
    Madsen F; Frølund L; Christensen M; Frost A; Petersen US
    J Investig Allergol Clin Immunol; 2009; 19(4):253-9. PubMed ID: 19639720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allergen vial mixing and immunotherapy: Risks of infections and vial contamination.
    Lay PC; Bass R; Lin SY
    Otolaryngol Head Neck Surg; 2007 Aug; 137(2):243-5. PubMed ID: 17666249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allergen immunotherapy.
    Huggins JL; Looney RJ
    Am Fam Physician; 2004 Aug; 70(4):689-96. PubMed ID: 15338781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stinging insect allergy: state of the art 2015.
    Tankersley MS; Ledford DK
    J Allergy Clin Immunol Pract; 2015; 3(3):315-22; quiz 323. PubMed ID: 25956310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
    Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
    J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anaphylaxis in the allergy practice.
    Leatherman BD
    Int Forum Allergy Rhinol; 2014 Sep; 4 Suppl 2():S60-5. PubMed ID: 25182358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2.
    Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
    Ann Allergy Asthma Immunol; 2011 Nov; 107(5):426-431.e1. PubMed ID: 22018614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is allergy immunotherapy-induced anaphylaxis still a real problem?
    Bernstein DI; Berendts K
    Curr Opin Allergy Clin Immunol; 2022 Dec; 22(6):409-412. PubMed ID: 35980016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allergen immunotherapy: 100 years, but it does not look like.
    Frati F; Incorvaia C; Lombardi C; Senna G
    Eur Ann Allergy Clin Immunol; 2012 Jun; 44(3):99-106. PubMed ID: 22905590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medical-legal considerations in the practice of allergy: personal reflections on lessons learned from an immunotherapy fatality.
    Hallett JS
    Allergy Asthma Proc; 2004; 25(6):401-6. PubMed ID: 15709451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of anaphylaxis in cluster vs standard subcutaneous multiallergen immunotherapy.
    Chen JH; Orden T; Wang J; Sowho M; Tversky J
    Ann Allergy Asthma Immunol; 2023 May; 130(5):622-627. PubMed ID: 36521783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence to imported fire ant subcutaneous immunotherapy.
    Stokes SC; Quinn JM; Sacha JJ; White KM
    Ann Allergy Asthma Immunol; 2013 Mar; 110(3):165-7. PubMed ID: 23548525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.